Keyphrases
Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
95%
Chronic Rhinosinusitis
89%
Nasal Polyps
49%
Aspirin-exacerbated Respiratory Disease
37%
Asthma
35%
Nasal Polyposis
14%
Eosinophils
14%
Allergy
11%
ILC2
10%
Immunology
9%
Anaphylaxis
9%
Inflammation
9%
Thymic Stromal Lymphopoietin
8%
Type 2 Inflammation
8%
Interleukin-13 (IL-13)
8%
Allergic Reaction
8%
Bronchiectasis
8%
Allergic Rhinitis
7%
Aspirin
7%
Group 2 Innate Lymphoid Cells
7%
Patient-Reported Outcomes Measurement Information System (PROMIS)
7%
Inflammatory Endotype
7%
Aspirin Therapy
7%
Medical Management
6%
Respiratory Syncytial Virus
6%
Neutrophils
6%
Intranasal Corticosteroids
6%
Clinical Characteristics
6%
Aspirin Desensitization
6%
Tissue Plasminogen Activator (t-PA)
6%
Desensitization
6%
Disease Severity
6%
Uncinate
6%
Nasal Lavage Fluid
6%
Patient Characteristics
6%
Single-cell RNA Sequencing (scRNA-seq)
6%
Eosinophil Cationic Protein
5%
Acute Exacerbation
5%
Tertiary Care Hospital
5%
New Patients
5%
Non-cystic Fibrosis Bronchiectasis
5%
Clinical Presentation
5%
Basophils
5%
Dysregulation
5%
Disease Pathogenesis
5%
Control Subjects
5%
Respiratory Tract
5%
Nasal Tissue
5%
Interleukin-5 (IL-5)
5%
Endoscopic Sinus Surgery
5%
Medicine and Dentistry
Chronic Rhinosinusitis
100%
Nasal Polyp
67%
Aspirin Exacerbated Respiratory Disease
21%
Asthma
18%
Diseases
18%
Endotype
15%
Bronchiectasis
9%
Desensitization
8%
Prevalence
8%
Acetylsalicylic Acid
8%
Allergic Rhinitis
7%
Biological Product
7%
Interleukin 13
7%
Eosinophil
7%
Immunology
7%
Biological Marker
7%
Patient-Reported Outcome
7%
Lymphoid Cell
6%
Tertiary Care
6%
Polyp
5%
Fibrosis
5%
Cytokine
5%
Mediator
5%
Interleukin 5
5%
Immunology and Microbiology
Asthma
41%
Aspirin-Induced Asthma
33%
Prevalence
18%
Eosinophil Granulocyte
12%
Eosinophil
11%
Hypersensitive Response
10%
Thymic Stromal Lymphopoietin
9%
Computer Assisted Tomography
9%
Anaphylaxis
8%
Innate Lymphoid Cell
8%
Basophil Granulocyte
7%
Allergic Rhinitis
7%
Cytokine
7%
Immunoglobulin E
7%
Mast Cell
6%
RNA Sequence
6%
Human Respiratory Syncytial Virus
6%
Mediator
5%
COVID-19
5%
Immunology
5%
Immunocompetent Cell
5%
Interleukin 13
5%